# Safety and Efficacy of Exenatide Once Weekly Versus Liraglutide in Subjects With Type 2 Diabetes

Study · id `cardio:ct-nct01029886` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01029886](<https://clinicaltrials.gov/study/NCT01029886>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT01029886

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 912 participants.

## Technical summary

Registry record NCT01029886. Randomized; no masking; primary purpose treatment. Start 2010-01 (registry gives no type); primary completion 2011-01 (actual). Results posted on 2012-03-21.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 912 participants (enrolled count; ClinicalTrials.gov record NCT01029886, source copy `cardio:ctgov-nct01029886-2015-04-09`, retrieved 2026-10-26)
- Start date: 2010-01 (registry gives no type) (ClinicalTrials.gov record NCT01029886, source copy `cardio:ctgov-nct01029886-2015-04-09`, retrieved 2026-10-26)
- Primary completion: 2011-01 (actual) (ClinicalTrials.gov record NCT01029886, source copy `cardio:ctgov-nct01029886-2015-04-09`, retrieved 2026-10-26)
- Completion: 2011-04 (actual) (ClinicalTrials.gov record NCT01029886, source copy `cardio:ctgov-nct01029886-2015-04-09`, retrieved 2026-10-26)
- Results first posted: 2012-03-21 (ClinicalTrials.gov record NCT01029886, source copy `cardio:ctgov-nct01029886-2015-04-09`, retrieved 2026-10-26)
- Countries: Argentina; Australia; Austria; Belgium; Canada; Czechia; France; Germany; Greece; Hungary; India; Israel; Italy; Mexico; Poland; Romania; Slovakia; South Africa; South Korea; Spain; Taiwan (ClinicalTrials.gov record NCT01029886, source copy `cardio:ctgov-nct01029886-2015-04-09`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01029886-2015-04-09`, retrieved 2026-10-26)

## The registry's words

- Brief title: Safety and Efficacy of Exenatide Once Weekly Versus Liraglutide in Subjects With Type 2 Diabetes
- Condition: Type 2 Diabetes Mellitus
- Intervention (Drug): exenatide once weekly
- Intervention (Drug): liraglutide
- Lead sponsor: AstraZeneca
- Lead sponsor class: INDUSTRY
- Collaborator: Eli Lilly and Company
- Collaborator class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry lists this organization as the lead sponsor: AstraZeneca (`cardio:astrazeneca`)
- Registry lists this organization as a collaborator: Eli Lilly and Company (`cardio:eli-lilly`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): a randomised, open-label study (`cardio:pubmed-23141817`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: 11123d64bbb49df0f652fc6a9a1ec2d1d1a1147b8dc5019a3d9b30c56f03bd45
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
